Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 16Recruiting 7Active not recruiting 4Not yet recruiting 3Unknown 1Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Other hematologic neoplasm 2Genitourinary 2Tumor-Agnostic 1Sarcoma 1Other neoplasm 1Other 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Ventricular Dysfunction, Left 1Motor Activity 1Lymphoma 1Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1Breast Diseases 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Exercise × Lymphoid × Clear all
NCT03850171 2023-02-27

Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study

Insel Gruppe AG, University Hospital Bern

Phase NA Terminated
57 enrolled
BreastLymphoid

Breast Diseases, Breast Neoplasms, Heart Failure, Lymphoma, Motor Activity, Ventricular Dysfunction, Left, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡